Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.


19 02, 2015

BREAKING NEWS: Revlimid receives expanded FDA approval

Tags: , , |2 Comments

I received some good news from Eliza Schleifstein with Cegene.  She passed along this information for me to share: Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for REVLIMID® (lenalidomide) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma. The treatment is

26 07, 2014

Myeloma News

Tags: , |11 Comments

Here's some myeloma related news I've been saving to pass along.  I include an update about how I'm doing at the end. reports that bone marrow donor matches are more common than most thought.  Here's an excerpt and link: Good Odds for Those Who Need Bone Marrow Donor, Study Finds Most blood cancer patients

23 06, 2014

Celgene Patient Support to the rescue!

Tags: , , , |5 Comments

Last week I became concerned after Cigna Insurance delayed approval of my new, oral myeloma therapy, Pomalyst (pomalidomide).  After not hearing anything for three days, I contacted Celgene Patient Support. I was immediately connected with Senior Patient Support Specialist for the Jacksonville, Florida area, Kelly Jones.  Kelly spent 20 minutes on the phone with me,

11 08, 2013

EU approves pomalidomide and broader use of Velcade

Tags: , , , , , , , |8 Comments

Europe's Regulatory Commission (EC) has been busy lately.  Sort of like our FDA, the EC approved a broader use of Velcade, then gave the green light for use of Pomalyst in relapsed patients: European Commission Approves VELCADE® As A Frontline Induction Therapy Before Stem Cell Transplantation   Decision could significantly improve transplant outcomes for patients

30 07, 2013

What’s a billion dollars among friends?

Tags: , , , , |8 Comments

Ever take Revlimid?  Wonder where the tens of thousands of dollars that Medicare or your private insurance company pays for it goes each month?  To finance speculative acquisitions of small, start-up pharmaceutical companies, of course! A few short weeks after acquiring the rights to one of the hottest yet unproven anti-myeloma therapy agents, MorphoSys' MOR202,

1 07, 2013

More about MOR202

Tags: , , , |1 Comment

Yesterday's post generated quite a bit of interest.  Here's what I know about CD38 and MOR202  In January 2012, a 19 year old company that specializes in human antibody research, MorphoSys, received a U.S. patent for MOR202, a fully human HuCAL antibody.  This new antibody was designed to use CD38 as a therapeutic target for

17 04, 2013

What took so long? Pomalidomide time-line raises questions–I have answers (Part Three)

Tags: , , , , , , , , , |5 Comments

I stuck with the original heading for the third installment of my three part investigative expose'.  But today's post could have been titled, "Different shades of grey."   Pomalidomide's development was shaped by a convoluted system that does a poor job balancing patient need with investor returns. But I'm getting ahead of myself.  Yesterday I promised

16 04, 2013

What took so long? Pomalidomide time-line raises questions–I have answers (Part Two)

Tags: , , , , , , , , , , , |7 Comments

Before I get started, did you happen to see the MMRF's Kathy Giusti interviewed in the trendy tech magazine, Fast Company?  Interesting approach.  Simply click-on the headline link below to access the interview: Using Data To Treat Cancer And Drive Innovation How a pair of savvy renegades are forcing collaboration in cancer R&D--and saving lives.

9 02, 2013

Everything you always wanted to know about POM but were afraid to ask…

Tags: , , , , , , , , , , , , |4 Comments

The internet is flooded with excitement following the FDA's limited approval of celgene's newest IMiD, pomalidomide (trade name, POMALYST).  POM is an analogue of thalidomide (trade name, Thalomid).  Researchers actually developed POM before Revlimid, but sat on it for a decade--choosing to intensify clinical study activity recently, culminating in yesterday's FDA approval. I'm going to

8 02, 2013

Celgene: FDA approval of POM “based on response rate.”

Tags: , , , , , |7 Comments

Here's Celgene's official press release about today's FDA approval of pomalidomide.  I will review what the news means to me--and my fellow patients and caregivers--this weekend. U.S. FOOD AND DRUG ADMINISTRATION APPROVES POMALYST® (POMALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA SUMMIT, NJ – (Feb. 8, 2013) – Celgene Corporation (NASDAQ:

8 02, 2013

BREAKING NEWS: FDA approves pomalidomide

Tags: , , , |0 Comments

Celgene spokesperson, Greg Geissman, emailed me four minutes ago with the good news: U.S. FOOD AND DRUG ADMINISTRATION APPROVES POMALYST® (POMALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA Official press release to follow. Feel good and keep smiling!  Pat

8 01, 2013

POMALYST? What happened to Actimid?

Tags: , , , |10 Comments

I emailed my Celgene contact, Greg Geissman, last evening after learning that pomalidomide's trade name would be POMALYST.  My question:  What happened to the anticipated trade name, Actimid? Actimid, wow, blast from the past, I think we stopped using that proposed name a few years back. We had been simply going by the generic name